The First Anti-Aging Drug for Dogs Just Cleared a Major FDA Hurdle — Here's What It Means

If you've ever wished for more time with your dog, science may soon have an answer. A San Francisco-based biotech company called Loyal is on the verge of making history — and clearing one of the final hurdles to bring the first-ever FDA-approved anti-aging drug for dogs to your veterinarian's office.

In January 2026, Loyal announced that the FDA's Center for Veterinary Medicine accepted the safety package for LOY-002, the company's lead drug designed to extend the healthy lifespan of senior dogs. It's a milestone that brings us closer than ever to a world where "a few more good years" isn't just wishful thinking — it's a prescription.

What Is LOY-002 and How Does It Work?

LOY-002 is a daily flavored chewable tablet designed for senior dogs aged 10 and older, weighing at least 14 pounds. Unlike treatments that target a specific disease after it's already appeared, LOY-002 takes a preventive approach — addressing the underlying metabolic dysfunction that all dogs experience as they age.

As dogs get older, their metabolism gradually breaks down in ways that trigger a cascade of age-related diseases: arthritis, kidney disease, cognitive decline, cancer. LOY-002 aims to slow that process at its root, delaying the onset of these conditions and preserving your dog's quality of life for longer.

"Our general strategy for extending healthy lifespan in dogs is to use our understanding of the fundamental biology of aging to target specific aging mechanisms that reduce the quality and length of life," Loyal explained in their announcement. "Rather than waiting for aging to damage health and then reacting to the diseases that occur, we take a proactive approach."

Where Does LOY-002 Stand With the FDA?

Getting an anti-aging drug approved is uncharted territory — for any species. Loyal is pursuing the FDA's Expanded Conditional Approval (XCA) pathway, which requires three key components:

1. Reasonable Expectation of Effectiveness (RXE) — Accepted by the FDA in February 2025
2. Target Animal Safety (TAS) — Accepted by the FDA in January 2026
3. Manufacturing standards — Currently in progress

With two of three requirements completed, LOY-002 is closer to approval than any dog longevity drug in history. The safety data was particularly impressive: Loyal tested the drug in over 400 dogs at up to five times the intended dose, and reported no clinically significant adverse events.

"We've studied LOY-002 in hundreds of dogs, including those with many of the health conditions and medical treatments senior dogs often experience," Loyal stated, "and we are extremely pleased the FDA agrees that these data support the safety of LOY-002 for its intended use."

The STAY Study: 1,300 Dogs, 70 Clinics, One Big Question

While Loyal works toward conditional approval, they're simultaneously running the STAY study — a massive double-blind, placebo-controlled clinical trial with 1,300 senior dogs enrolled at 70 veterinary clinics across the United States.

The study will span up to four years, with participating dogs receiving either LOY-002 or a placebo as a daily chewable. Dog owners bring their pets in for six study visits in the first year, then twice annually after that. The results of the STAY study will support Loyal's application for full FDA approval.

It's the kind of rigorous, large-scale trial that's rarely been attempted in veterinary medicine — and one that could reshape how we think about aging in our pets.

Not Just LOY-002: Loyal's Full Pipeline

LOY-002 isn't Loyal's only project. The company, which recently raised $100 million in a Series C funding round, is developing multiple drugs targeting different aspects of canine aging:

• LOY-001: An injectable for large dogs aged 7 and older (40+ lbs), targeting the overexpression of IGF-1 and growth hormone — one of the main reasons larger breeds tend to have shorter lifespans.
• LOY-003: For very large dogs aged 5 and older (60+ lbs), addressing the same growth hormone pathway with a different formulation.

"When you think about the company 10 years out, I think we'll be a multi-subsidiary company that's developing numerous products for dog longevity, probably for cat longevity by that time, and also human drugs," CEO Celine Halioua said in a February 2026 interview.

Rapamycin: The Other Dog Longevity Drug Being Studied

Loyal isn't the only team working on dog longevity. The Dog Aging Project — a major research initiative based at Texas A&M University — is studying rapamycin, a drug originally used as an immunosuppressant in organ transplant patients, for its potential anti-aging effects in dogs.

The project's TRIAD (Test of Rapamycin in Aging Dogs) clinical trial is the first rigorous test of an anti-aging drug with lifespan as a primary endpoint ever conducted outside a laboratory in any species. After a funding scare in 2024, the project was rescued by a five-year, $7 million grant from the National Institutes of Health.

"We all want our dogs to live longer, healthier lives," said Dr. Kate Creevy, the study's co-principal investigator, in an interview with AVMA News. The results could have implications not just for dogs, but for human aging research as well.

What This Means for Dog Owners Right Now

Let's be clear: there is no FDA-approved anti-aging drug for dogs available today. LOY-002 is still working through the approval process, and the rapamycin studies are ongoing. Some veterinarians do prescribe rapamycin off-label, but this should only be done under direct veterinary supervision with a clear understanding of the risks.

In the meantime, there's plenty you can do to help your dog age well:

• Regular veterinary checkups: Senior dogs (7+) should see the vet at least twice a year. Early detection of age-related conditions makes a huge difference.
• Maintain a healthy weight: Obesity is one of the biggest modifiable risk factors for a shorter lifespan in dogs. Work with your vet on a nutrition plan.
• Keep them active: Regular exercise — adjusted for age and ability — supports joint health, cardiovascular function, and mental sharpness.
• Mental stimulation: Puzzle toys, training sessions, and new experiences help prevent cognitive decline.
• Dental care: Dental disease is linked to heart, kidney, and liver problems. Regular cleanings matter.

A New Chapter in the Human-Dog Bond

The idea that we might one day give our aging dogs a daily pill to help them stay healthy longer isn't science fiction anymore — it's clinical science, backed by hundreds of millions of dollars in research and some of the most rigorous veterinary trials ever conducted.

For the 65 million American households with a dog, the promise of LOY-002 is deeply personal. It's the promise of more morning walks, more tail wags, more years of that unconditional love that makes the bond between people and dogs unlike anything else.

We'll be keeping a close eye on Loyal's progress and the Dog Aging Project's findings. In the meantime, give your pup an extra treat tonight — and know that science is working hard to give you both more time together.

At Sidewalk Dog, we're all about helping you and your pup live your best lives — from finding dog-friendly spots in your city to keeping you informed on the latest in dog health and wellness. Want more stories like this delivered to your inbox? Sign up for our newsletter.